On June 10, 2008, Daiichi Sankyo agreed to take a majority (35%) stake in Indian generic drug maker Ranbaxy, with a deal valued at about $4.6 billion.
•
The company also owns the American biotechnology company Plexxikon, the German biotechnology company U3 and Ranbaxy Laboratories in India.
In June 2008, Japan's Daiichi Sankyo Company took a majority (50.1%) stake in Ranbaxy, with a deal valued at about US$4.6 billion.
Abbott Laboratories | Sandia National Laboratories | Gold Standard Laboratories | Wang Laboratories | Dolby Laboratories | Chalk River Laboratories | Dr. Reddy's Laboratories | Ranbaxy Laboratories | Mitsubishi Electric Research Laboratories | Nevis Laboratories | Forest Laboratories | CBS Laboratories | Wyle Laboratories | Wolfe Laboratories | Whiteshell Laboratories | Unix System Laboratories | Stiefel Laboratories | Scientific Protein Laboratories | National Training Laboratories | Nationally Recognized Testing Laboratories | National Aerospace Laboratories | National Accreditation Board for Testing and Calibration Laboratories | Machlett Laboratories | Khan Research Laboratories | Ken'ichirÅ Mogi, Senior Researcher of the Sony Computer Science Laboratories | Friday Harbor Laboratories | DuMont Laboratories | Danco Laboratories | Cutter Laboratories | Bio-Rad Laboratories |
However a generic version manufactured by Japanese-owned Indian company Daiichi-Ranbaxy was found by the District Court of New Jersey, USA not to infringe Roche's patent.